SCHEMBL29615841

SCHEMBL29615841

CCc1cccnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10607 1.00
Ammonia Solution, Strong SCHEMBL5999609 0.98
Iodide SCHEMBL29656767 0.98
Bromide SCHEMBL17353583 0.98
Hydrochloric Acid SCHEMBL9846665 0.98
Hydrochloric Acid SCHEMBL11425908 0.98 ALDH1A1 (0.63)
Cyanide SCHEMBL30330228 0.93 ALDH1A1 (0.59)
SCHEMBL11860127 0.93 ALDH1A1 (0.59)
Dimethylamine SCHEMBL10843147 0.93 ALDH1A1 (0.65)
Alcohol SCHEMBL943866 0.93 ALDH1A1 (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346922-A1 COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION TENAYA THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12201617-B2 HDAC6 inhibitors for treatment of metabolic disease and HFpEF TENAYA THERAPEUTICS, INC. (US) 2025-01-21 US disclosed
US-20240252502-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2024-08-01 US disclosed
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2024-04-11 US disclosed
US-20240066001-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES SILTI AG (CH) 2024-02-29 US disclosed
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2023-11-30 US disclosed
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-05-11 US disclosed
CN-114394913-B Synthetic method of oxime ether derivative 山东农业大学 2023-02-03 CN disclosed
CN-114394913-A Synthetic method of oxime ether derivative 山东农业大学 2022-04-26 CN disclosed